Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO
Invectys, Inc.May 4, 2021 GMT
Houston, TX, USA, May 04, 2021 (GLOBE NEWSWIRE) Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced the appointment of Praveen Tyle, PhD, as President & CEO and election to its Board of Directors. Dr. Tyle brings over 35 years of experience in both large and small pharma and biotech companies, most recently serving as Executive V.P. for Research and Development of the public company, Lexicon Pharmaceuticals, Inc. Earlier, Dr. Tyle served as the Corporate Senior Vice President and Chief Scientific Officer of Bausch and Lomb and then as Senior Vice President and Global Head of Business Development and R&D at Novartis OTC. Subsequently, Dr. Tyle joined
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adamas Pharma - Starting The Year Off Right?
WASHINGTON (dpa-AFX) - Shares of Adamas Pharmaceuticals Inc. (ADMS) have recovered 140% from their 52-week low of $1.90 recorded on Mar.18, 2020, and trade around $4.50.
Adamas is a commercial-stage pharmaceutical company with a growing portfolio of therapies for neurological diseases. The company s flagship product is GOCOVRI, a FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medicines.
The sales of GOCOVRI have increased over the years ever since its launch in the fourth quarter of 2017. The drug raked in sales of $568 thousand in 2017; $34.05 million in 2018; $54.64 million in 2019; and $51.5 million in the nine months ended Sep.30, 2020.
Author Bio
A Fool since 2019, Prosper s writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances and enjoys it just as much when they return the favor. In his free time, you ll find him curling up with a good book or doing math.
What happened?
Shares of
Osmotica Pharmaceuticals (NASDAQ:OSMT), a biopharmaceutical company, dropped by as much as 24.4% on Wednesday and closed today s trading session down by 20%. Investors sold off shares of the company following its announcement that the U.S. Food and Drug Administration (FDA) has declined to approve one of its products.